Apellis Pharmaceuticals secured a royalty purchase agreement with Sobi, while also awaiting FDA regulatory decisions, amid AI stock trends benefiting from tariffs.
2 reports, 0 independent
Updated Jul 6
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Apellis Pharmaceuticals secured a royalty purchase agreement with Sobi, while also awaiting FDA regulatory decisions, amid AI stock trends benefiting from tariffs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Apellis partners with Sobi and awaits FDA approval, while AI stocks benefit from tariffs.
- Specific details emerged regarding the royalty purchase agreement between Apellis and Sobi.
Keep exploring
The entities involved
-
Apellis Pharmaceuticals (United States)
company in Crestwood, United States
Nothing else this week.
-
sobi
German beverage store chain
Nothing else this week.
- FDA
Related events
- RedHill Biopharma's stock surged on Nasdaq following the divestment of its Talicia business to Apotex for $18M, while future products seek FDA approval.
- MiniMed Group received multiple target price increases from UBS, Morgan Stanley, and Deutsche Bank, and submitted a product to the FDA.
- FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
- Acurx Pharmaceuticals trades on NASDAQ and is receiving FDA guidance supporting its potential approval pathway.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet